About
About Boya Bio-pharmaceutical Group Co.,Ltd
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound bone peptide, oxytocin, heparin sodium injection, posterior pituitary, and carboprost tromethamine injection. In addition, it engages in research, development, production, and sales of anti-infective, diabetes, and cardiovascular drugs. The company was formerly known as Boya Bio-pharmaceutical Group Co., Ltd. and changed its name to China Resources Boya Bio-pharmaceutical Group Co.,Ltd. The company was founded in 1993 and is based in Fuzhou, China.
Visit company website
5 years, 5 months ago
Boya Bio-pharmaceutical Group Co.,Ltd is currently in a long term uptrend where the price is trading 17.5% above its 200 day moving average.
From a valuation standpoint, the stock is 53.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.5.
Boya Bio-pharmaceutical Group Co.,Ltd's total revenue sank by 9.0% to $661M since the same quarter in the previous year.
Its net income has dropped by 40.4% to $63M since the same quarter in the previous year.
Finally, its free cash flow grew by 216.7% to $215M since the same quarter in the previous year.
Based on the above factors, Boya Bio-pharmaceutical Group Co.,Ltd gets an overall score of 3/5.